ATE227727T1 - Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen - Google Patents

Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen

Info

Publication number
ATE227727T1
ATE227727T1 AT97934774T AT97934774T ATE227727T1 AT E227727 T1 ATE227727 T1 AT E227727T1 AT 97934774 T AT97934774 T AT 97934774T AT 97934774 T AT97934774 T AT 97934774T AT E227727 T1 ATE227727 T1 AT E227727T1
Authority
AT
Austria
Prior art keywords
compound
inventive compound
useful
pharmaceutically acceptable
thienotriazolodiazepine compounds
Prior art date
Application number
AT97934774T
Other languages
English (en)
Inventor
Hiroyuki Sueoka
Hirotsugu Komatsu
Haruhito Kobayashi
Syuji Ehara
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of ATE227727T1 publication Critical patent/ATE227727T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97934774T 1996-09-13 1997-08-11 Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen ATE227727T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24379396 1996-09-13
PCT/JP1997/002817 WO1998011111A1 (en) 1996-09-13 1997-08-11 Thienotriazolodiazepine compounds and medicinal uses thereof

Publications (1)

Publication Number Publication Date
ATE227727T1 true ATE227727T1 (de) 2002-11-15

Family

ID=17109041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934774T ATE227727T1 (de) 1996-09-13 1997-08-11 Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen

Country Status (14)

Country Link
EP (1) EP0989131B1 (de)
JP (1) JP3094453B2 (de)
KR (1) KR100338144B1 (de)
CN (1) CN1109037C (de)
AT (1) ATE227727T1 (de)
AU (1) AU716490B2 (de)
CA (1) CA2265645C (de)
DE (1) DE69717160T2 (de)
DK (1) DK0989131T3 (de)
EA (1) EA001732B1 (de)
ES (1) ES2182108T3 (de)
NO (1) NO323892B1 (de)
PT (1) PT989131E (de)
WO (1) WO1998011111A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2006129623A1 (ja) * 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
EP3050885B1 (de) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine-bromodomänenhemmer
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP2571875A4 (de) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc Zusammensetzungen für männliches verhütungsmittel und verfahren zur verwendung
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
GB201020015D0 (en) * 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CA2870931A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
AU2013283378B2 (en) * 2012-06-25 2017-07-13 Oncoethix Gmbh Method of treating lymphoma using thienotriazolodiazepine compounds
EP2885286B1 (de) 2012-08-16 2017-03-22 Bayer Pharma Aktiengesellschaft 2,3-benzodiazepine
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
EP2900672B1 (de) 2012-09-28 2017-02-22 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
EP2970312B1 (de) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet-bromdomänenhemmer und therapeutische verfahren damit
WO2014159392A1 (en) * 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CN106029077A (zh) * 2013-08-01 2016-10-12 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
CN103694253A (zh) * 2013-11-04 2014-04-02 湖南华腾制药有限公司 一种噻吩并三唑并[4,3-a][1,4]二氮杂卓类化合物的制备方法
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (de) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidinbenzolsulfonderivate und verwendungen davon
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN105940005A (zh) 2014-01-31 2016-09-14 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス,インコーポレイテッド 高インスリン血症に関連した症状の処置
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3262045A1 (de) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido[4,5-b]indole als bet-bromdomänen-hemmer
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3347021A4 (de) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. Cyanothienotriazoldiazepine und verwendungen davon
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
US11548899B2 (en) 2016-02-15 2023-01-10 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
KR20180132861A (ko) 2016-04-12 2018-12-12 더 리젠츠 오브 더 유니버시티 오브 미시간 Bet 단백질 분해제
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (de) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclische degronimere für zielproteinabbau
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CA3036834A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CA3041949A1 (en) 2016-12-16 2018-06-21 F. Hoffmann-La Roche Ag Process for the manufacture of diazepine derivatives
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
CN110914280B (zh) * 2017-05-31 2024-05-03 阿尤米制药公司 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂䓬衍生物
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
EP3773576A4 (de) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon-bindemittel zum abbau von ikaros
EP3781156A4 (de) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. Spirocyclische verbindungen
AU2019284971A1 (en) 2018-06-13 2020-12-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Preparation of condensed triazepine derivatives and their use as BET inhibitors
EP3819305A4 (de) 2018-07-04 2022-04-06 Mitsubishi Tanabe Pharma Corporation Amidverbindung mit bet-proteolyse-induzierender wirkung und deren medizinische verwendung
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
JP7292400B2 (ja) * 2019-03-07 2023-06-16 メッドシャイン ディスカバリー インコーポレイテッド BET Bromodomainタンパク質の阻害とPD-L1遺伝子の調節の両方の効果を持つ化合物
JP7419406B2 (ja) 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Brd4蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
WO2022048685A1 (zh) * 2020-09-07 2022-03-10 南京明德新药研发有限公司 苯并四氢呋喃肟类化合物的晶型及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62181282A (ja) * 1986-01-21 1987-08-08 ベ−リンガ− インゲルハイム コマンデイツト ゲゼルシヤフト チエノ−1,4−ジアゼピン
EP0368175A1 (de) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
YU133090A (sh) * 1989-07-12 1993-10-20 Boehringer Ingelheim Kg. Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo
WO1994006801A1 (fr) * 1990-05-23 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation comme medicament
DE4027470A1 (de) * 1990-08-30 1992-03-05 Boehringer Ingelheim Kg Neue hetrazepinoide amide
EP0638560A4 (de) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical Heilmittel für osteoporose und diazepinverbindung*.
DK0656361T3 (da) * 1991-12-11 2000-07-24 Yoshitomi Pharmaceutical Lægemiddel til behandling af autoimmune sygdomme
JP3215489B2 (ja) * 1992-04-23 2001-10-09 日本電信電話株式会社 燃料電池排熱利用システムとその制御方法
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
EP0692483A1 (de) * 1993-03-30 1996-01-17 Yoshitomi Pharmaceutical Industries, Ltd. Zelladhäsionsinhibitor und thienotriazoldiazepin-derivat
JP3633008B2 (ja) * 1993-11-15 2005-03-30 三菱ウェルファーマ株式会社 チエノトリアゾロジアゼピン化合物
JPH0879471A (ja) * 1994-09-01 1996-03-22 Konica Corp 画像形成装置

Also Published As

Publication number Publication date
KR20000036057A (ko) 2000-06-26
ES2182108T3 (es) 2003-03-01
EP0989131A4 (de) 2000-03-29
AU3786097A (en) 1998-04-02
PT989131E (pt) 2003-03-31
EP0989131A1 (de) 2000-03-29
CN1237180A (zh) 1999-12-01
DE69717160D1 (de) 2002-12-19
AU716490B2 (en) 2000-02-24
CA2265645C (en) 2007-01-23
NO323892B1 (no) 2007-07-16
NO991191L (no) 1999-04-23
CN1109037C (zh) 2003-05-21
HK1023571A1 (en) 2000-09-15
DK0989131T3 (da) 2003-03-03
WO1998011111A1 (en) 1998-03-19
JP3094453B2 (ja) 2000-10-03
CA2265645A1 (en) 1998-03-19
EA001732B1 (ru) 2001-08-27
NO991191D0 (no) 1999-03-11
EA199900287A1 (ru) 1999-08-26
KR100338144B1 (ko) 2002-05-24
DE69717160T2 (de) 2003-05-08
EP0989131B1 (de) 2002-11-13

Similar Documents

Publication Publication Date Title
ATE227727T1 (de) Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
NO171785C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater
ATE232531T1 (de) Heterobizyklische derivate
AU8531101A (en) Immunoregulatory compounds and derivatives and methods of treating diseases therewith
SE9901573D0 (sv) New compounds
IL165181A0 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
DK0570294T3 (da) 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
GR3019917T3 (en) Benzimidazole derivatives as antimicrobal agent against campylobacter pylon
NO905620L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
SE9901572D0 (sv) New compounds
KR970703147A (ko) 동맥경화 억제제(Arteriosclerosis Depressant)
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
DK0876144T3 (da) Terapeutiske anti-astmamidler indeholdende organiske selenforbindelser
EP2266566A3 (de) Nicotinamid Derivate und ihrer Verwendung als Therapeutika
ATE168690T1 (de) Indolderivate, ihre salze und sie enthaltende arzneimittel zur behandlung von herzkrankheiten
SE0103272D0 (sv) Chemical compounds
ATE109003T1 (de) Therapeutisches mittel gegen pollakiurie, harndrang oder harninkontinenz, das alpha-phenyl- alpha-pyridylalkan-carbonsäurederivate enthält.
EP0274230A3 (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
DK0638587T3 (da) Salmyciner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
TH50173A (th) การใช้ 1-ไฮดรอกซี-2-ไพริโดนสำหรับการบำบัดการติดเชื้อที่ผิวหนัง
TH17299A (de)
TH53156A3 (th) สารประกอบเฮทเทอโรไซคลิกและการใช้สารประกอบเฮทเทอโร-ไซคลิกในการรักษาโรค

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0989131

Country of ref document: EP